"We are delighted to do this new deal with GSK," said Dr.
About Locked Nucleic Acid (LNA) Drug Platform The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver LNA-based drug candidates against both mRNA and microRNA, thus enabling scientists to develop drug candidates against diseases that are difficult, or impossible, to target with contemporary drug platforms such as antibodies and small molecules. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA technologies through a unique combination of small size and very high affinity that allows this new class of drugs candidates to potently and specifically inhibit RNA targets in many different tissues without the need for complex delivery vehicles. LNA is also sometimes referred to as BNA (Bicyclic or Bridged Nucleic Acid).
Keywords for this news article include: Pharmaceutical Companies, Therapy, Drug Development, Santaris Pharma A/S,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Major Phone Makers Sign Anti-Phone-Theft Pledge
- India Recognizes Transgender People as 'Third Gender'
- 'Beige Book' Federal Reserve Survey, April 2014: Full Text
- Brands Get Caught in Bitter-Tweet Traps
- Michael Bloomberg Takes Aim at the NRA
- U.S. Job Market Still Needs Fed Stimulus: Yellen
- Yellen Remarks, Market Data Give Stocks a Boost
- Dems in Energy States Back Away From Obama
- Man Arrested After Driving Stolen Car to Court Hearing
- Depp, Pfister Are Tech Philosophers